- The shares of Amgen, Inc. (NASDAQ: AMGN) have received a price target increase from $266 to $275 by Oppenheimer. These are the details.
The shares of Amgen, Inc. (NASDAQ: AMGN) have received a price target increase from $266 to $275 by Oppenheimer. And Oppenheimer analyst Jay Olson is maintaining an “Outperform” rating on the company shares.
Olson pointed out that Tezepelumab for severe asthma NDA/MAA are being planned for the first half of this year. And this could expand into chronic obstructive pulmonary disease (COPD) and urticaria.
Plus Olson has been encouraged by olpasiran, a small interfering RNA (siRNA) that inhibits Lp(a) for Atherosclerotic Cardiovascular Disease (ASCVD) patients with an ongoing Phase 2 trial. Olson forecasted risk-adjusted olpasiran sales of $1.5 billion in 2030.
Some of the other value drivers for the company included bemarituzumab from the Five Prime acquisition, the BiTE program, inflammation candidates, and biosimilars.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
